source
- Genmab reports phase 3 success for Elahere competitor and previews Merus buyout dataGenmab disclosed at the European Society for Medical Oncology meeting that its experimental therapy, positioned as a rival to Elahere, achieved a positive outcome in a phase 3 trial. The result si…
- Amgen and AstraZeneca present new combo data for extensive-stage small cell lung cancer at ESMODay two of the European Society for Medical Oncology meeting in Madrid saw nearly 40,000 attendees gathering for the latest cancer research updates, as reported in the STAT+ newsletter. The sessio…